Hematological and toxicological parameters after metformin treatment during pancreatic carcinogenesis | ||||
Egyptian Journal of Cancer and Biomedical Research | ||||
Article 5, Volume 3, Issue 2 - Serial Number 4, August 2019, Page 23-29 PDF (1.95 MB) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/jcbr.2019.37783 | ||||
![]() | ||||
Authors | ||||
Mohamed A. M. Hegazi![]() | ||||
1Zoology Department, Faculty of Science, Tanta University, Tanta 31527-Egypt. | ||||
2Zoology Department, Faculty of Science, Tanta University, Egypt | ||||
Abstract | ||||
Pancreatic cancer is the fourth-highest cancer killer among both men and women worldwide. In Egypt, pancreatic cancer incidence and mortality rates has been increasing in the last few years due to unknown reasons. The biguanides metformin is the most widely used first-line therapy for type 2 diabetes (T2D). Numerous observational studies have supported a protective role for metformin against a variety of cancer types as breast, liver and prostate cancer. This study aimed to investigate the anti-tumor effects of metformin treatment against pancreatic cancer induced in Syrian golden hamsters.by subcutaneous injection of A/-nitrosobis (2-oxopropyl) amine (BOP). Gemcitabine was used as a conventional drug used for treatment of pancreatic cancer. The results show that metformin has no toxic effect against chemically induced pancreatic carcinogenesis of hamsters caused by BOP induction. | ||||
Keywords | ||||
Metformin; Hamsters; Pancreatic cancer; N-Nitrosobis (2-oxopropyl) amine | ||||
Statistics Article View: 184 PDF Download: 135 |
||||